Dong-A ST Co., a drug ingredient-making subsidiary of Dong-A Socio Holdings Co., announced on Feb. 6 that it has completed construction of a biopharmaceutical production plant in Indonesia to push into the local market.
The US$15 million (16.21 billion won) plant was established by a joint investment with its Indonesia's partner company Combiphar.
It is located in Jababeka Industrial Complex near Jakarta, the capital of Indonesia. With total areas of 10,000 square meters and total floor areas of 4,400 square meters, the plant has production facilities, waste treatment facilities and hazardous material treatment facilities in a building with three stories. It can produce 4.7 million free-field injections annually. The two companies expect that the plant will become fully operational in 2020 after validation of various equipment and production processes, while also receiving local GMP certification.
After the plant starts its operation, Dong-A ST will export raw biopharmaceutical materials for its products such as Eporon, an anemia treatment for chronic renal failure patients, and Leucostim, a neutropenia treatment, to the plant. Combiphar will be in charge of production and local marketing.
Before the full-scale operation of the plant, Dong-A ST also plans to export the completed products of Eporon and Leucostim through Combiphar to secure product recognition in the Indonesian market.